Results 121 to 130 of about 45,216 (237)

Supplementary Table 3 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis [PDF]

, 2023
Alessandro Prete, Agnes S. Lo, Peter M. Sadow, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John G. Clohessy, Ann M. Dvořàk, Tracey Sciuto, Manoj Bhasin, Joanne E. Murphy-Ullrich, Jack Lawler, S. Ananth Karumanchi, Carmelo Nucera   +15 more
openalex   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease [PDF]

, 2012
Background The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients.
Chan, P, Cheung, TT, Fan, ST, Pang, R, Poon, RT, Wong, H, Yao, TJ, Yau, T   +7 more
core   +1 more source

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB ...
Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa, Yasuyuki Komiyama, Hitomi Takada, Shuya Matsuda, Masaru Muraoka, Mitsuaki Sato, Shinya Maekawa, Nobuyuki Enomoto, Hisanori Muto, Yoshihiko Tachi, Yoshiki Hirooka, Atsunori Tsuchiya   +13 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2019
Background Sorafenib is the first-line treatment for advanced-stage hepatocellular carcinoma (HCC). Several studies have shown that the up-regulation of β-catenin plays a role in sorafenib resistance in HCC; however, the mechanism associated with this ...
Ling Deng, Jingyuan Sun, Xiaohui Chen, Li Liu, Dehua Wu   +4 more
doaj   +1 more source

Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma

, 2021
Wei Yuan, Ran Tao, Da Huang, Weiming Yan, Guanxin Shen, Qin Ning   +5 more
openalex   +2 more sources

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, EarlyView.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma [PDF]

, 2016
Hsin‐An Chen, Tsang‐Chih Kuo, Chi‐Feng Tseng, Jui‐Ti Ma, Shuting Yang, Chia‐Jui Yen, Ching‐Yao Yang, Shian‐Ying Sung, Jen‐Liang Su   +8 more
openalex   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source